tiprankstipranks
Trending News
More News >
Elekta AB Unsponsored ADR Class B (EKTAY)
:EKTAY

Elekta AB (EKTAY) Price & Analysis

Compare
23 Followers

EKTAY Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.02%<0.01%99.97%
Insiders
0.02%
Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors

EKTAY FAQ

What was Elekta AB Unsponsored ADR Class B’s price range in the past 12 months?
Elekta AB Unsponsored ADR Class B lowest stock price was $4.43 and its highest was $7.20 in the past 12 months.
    What is Elekta AB Unsponsored ADR Class B’s market cap?
    Elekta AB Unsponsored ADR Class B’s market cap is $1.92B.
      When is Elekta AB Unsponsored ADR Class B’s upcoming earnings report date?
      Elekta AB Unsponsored ADR Class B’s upcoming earnings report date is Aug 28, 2025 which is in 64 days.
        How were Elekta AB Unsponsored ADR Class B’s earnings last quarter?
        Elekta AB Unsponsored ADR Class B released its earnings results on May 28, 2025. The company reported -$0.098 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.098.
          Is Elekta AB Unsponsored ADR Class B overvalued?
          According to Wall Street analysts Elekta AB Unsponsored ADR Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Elekta AB Unsponsored ADR Class B pay dividends?
            Elekta AB Unsponsored ADR Class B pays a Semiannually dividend of $0.011 which represents an annual dividend yield of 0.43%. See more information on Elekta AB Unsponsored ADR Class B dividends here
              What is Elekta AB Unsponsored ADR Class B’s EPS estimate?
              Elekta AB Unsponsored ADR Class B’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Elekta AB Unsponsored ADR Class B have?
              Elekta AB Unsponsored ADR Class B has 368,588,000 shares outstanding.
                What happened to Elekta AB Unsponsored ADR Class B’s price movement after its last earnings report?
                Elekta AB Unsponsored ADR Class B reported an EPS of -$0.098 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.577%.
                  Which hedge fund is a major shareholder of Elekta AB Unsponsored ADR Class B?
                  Currently, no hedge funds are holding shares in EKTAY

                  Elekta AB Stock Smart Score

                  2
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -18.40%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  2.15%
                  Trailing 12-Months
                  Asset Growth
                  1.78%
                  Trailing 12-Months

                  Company Description

                  Elekta AB Unsponsored ADR Class B

                  Elekta AB (EKTAY) is a Swedish company specializing in the development and production of clinical solutions for treating cancer and brain disorders. The company operates in the healthcare sector and is renowned for its innovative medical devices and software solutions that enhance precision radiation therapy, radiosurgery, and brachytherapy. Elekta's core products include linear accelerators, treatment planning systems, and oncology information systems, which are used by healthcare providers globally to deliver effective treatment solutions.

                  EKTAY Company Deck

                  EKTAY Earnings Call

                  Q4 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call presented a mix of strong performance in Europe and solid financial metrics against challenges in the U.S. market, noncash impairments, and slight declines in certain regions like China. Overall, the company demonstrated resilience and positioned for future growth but faced significant hurdles that balanced the positive aspects.Read More>
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Haemonetics
                  Merit Medical Systems
                  QuidelOrtho
                  Staar Surgical
                  NovoCure
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis